Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and inclu...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-02, Vol.15 (4), p.1194 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 1194 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Van Gool, Stefaan W Makalowski, Jennifer Van de Vliet, Peter Van Gool, Stefanie Sprenger, Tobias Schirrmacher, Volker Stuecker, Wilfried |
| description | Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and include the OS of MGMT promoter-methylated (meth) adults with GBM. Unmeth (10 f, 18 m) and meth (12 f, 10 m) patients treated between 27 May 2015 and 1 January 2022 were analyzed retrospectively. There were no differences in age (median: 48 y) or Karnofsky performance index (median: 80). The IMI consisted of 5-day immunogenic cell death (ICD) therapies during TMZm: Newcastle disease virus (NDV) bolus injections and sessions of modulated electrohyperthermia (mEHT); subsequent active specific immunotherapy: dendritic cell (DC) vaccines plus modulatory immunotherapy; and maintenance ICD therapy. There were no differences in the number of vaccines (median: 2), total number of DCs (median: 25.6 × 10
), number of NDV injections (median: 31), and number of mEHT sessions (median: 28) between both groups. The median OS of 28 unmeth patients was 22 m (2y-OS: 39%), confirming previous results. OS of 22 meth patients was significantly better (
= 0.0414) with 38 m (2y-OS: 81%). There were no major treatment-related adverse reactions. The addition of IMI during/after standard of care should be prospectively explored. |
| doi_str_mv | 10.3390/cancers15041194 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9954396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743010310</galeid><sourcerecordid>A743010310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-9bf7986adf9abfcf0976d37d1fcc18a5d9dd2797d1576666018ed6ba32cda0003</originalsourceid><addsrcrecordid>eNptUk1P3DAQjaqigijn3ipLvfQSsOPEjnuotFAKkUA9lKpHy-uPXSPHTm2Hdvvr6xV0BYjxwaOZ957nWVNV7xA8xpjBEym81DGhDrYIsfZVddBA2tSEsPb1o3y_OkrpFpbAGFFC31T7mPQYdZgcVHbwyt5ZNQtn_2oFrmeX7RiUcGAYx9mHvNZRTBtgQgQLVboJ_LZ5DYYvlwj8tE7VN5tJg4vT609gAb5bv3IaDD5lm-eswfmfSUery6Bvqz0jXNJHD_dh9ePr-c3ZZX317WI4W1zVsu37XLOloawnQhkmlkYayChRmCpkpES96BRTqqGsFDpKSkDUa0WWAjdSia3Hw-rzve40L0etpPY5CsenaEcRNzwIy592vF3zVbjjjHUtZqQIfHwQiOHXrFPmo01SOye8DnPiDe0hpIg0XYF-eAa9DXP0xV5BUdY1rCmaO9RKOM2tN6G8K7eifEFbDBHEaDv38QuocpQerQxeG1vqTwgn9wQZQ0pRm51HBPl2QfizBSmM94-_Zof_vw74H-AFtxk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779529254</pqid></control><display><type>article</type><title>Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Van Gool, Stefaan W ; Makalowski, Jennifer ; Van de Vliet, Peter ; Van Gool, Stefanie ; Sprenger, Tobias ; Schirrmacher, Volker ; Stuecker, Wilfried</creator><creatorcontrib>Van Gool, Stefaan W ; Makalowski, Jennifer ; Van de Vliet, Peter ; Van Gool, Stefanie ; Sprenger, Tobias ; Schirrmacher, Volker ; Stuecker, Wilfried</creatorcontrib><description>Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and include the OS of MGMT promoter-methylated (meth) adults with GBM. Unmeth (10 f, 18 m) and meth (12 f, 10 m) patients treated between 27 May 2015 and 1 January 2022 were analyzed retrospectively. There were no differences in age (median: 48 y) or Karnofsky performance index (median: 80). The IMI consisted of 5-day immunogenic cell death (ICD) therapies during TMZm: Newcastle disease virus (NDV) bolus injections and sessions of modulated electrohyperthermia (mEHT); subsequent active specific immunotherapy: dendritic cell (DC) vaccines plus modulatory immunotherapy; and maintenance ICD therapy. There were no differences in the number of vaccines (median: 2), total number of DCs (median: 25.6 × 10
), number of NDV injections (median: 31), and number of mEHT sessions (median: 28) between both groups. The median OS of 28 unmeth patients was 22 m (2y-OS: 39%), confirming previous results. OS of 22 meth patients was significantly better (
= 0.0414) with 38 m (2y-OS: 81%). There were no major treatment-related adverse reactions. The addition of IMI during/after standard of care should be prospectively explored.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15041194</identifier><identifier>PMID: 36831536</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antigens ; Apoptosis ; Cancer therapies ; Care and treatment ; Cell cycle ; Cell death ; Chemotherapy ; Clinical trials ; Dendritic cells ; Glioblastoma ; Glioblastoma multiforme ; Immune system ; Immunogenicity ; Immunotherapy ; Lymphocytes ; Methods ; Neurosurgery ; Newcastle disease ; Oncolysis ; Patients ; Side effects ; Temozolomide ; Tumors ; Vaccines</subject><ispartof>Cancers, 2023-02, Vol.15 (4), p.1194</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-9bf7986adf9abfcf0976d37d1fcc18a5d9dd2797d1576666018ed6ba32cda0003</citedby><cites>FETCH-LOGICAL-c488t-9bf7986adf9abfcf0976d37d1fcc18a5d9dd2797d1576666018ed6ba32cda0003</cites><orcidid>0000-0002-2601-0878 ; 0000-0002-8102-5968 ; 0000-0003-1253-9145</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954396/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954396/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36831536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Gool, Stefaan W</creatorcontrib><creatorcontrib>Makalowski, Jennifer</creatorcontrib><creatorcontrib>Van de Vliet, Peter</creatorcontrib><creatorcontrib>Van Gool, Stefanie</creatorcontrib><creatorcontrib>Sprenger, Tobias</creatorcontrib><creatorcontrib>Schirrmacher, Volker</creatorcontrib><creatorcontrib>Stuecker, Wilfried</creatorcontrib><title>Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and include the OS of MGMT promoter-methylated (meth) adults with GBM. Unmeth (10 f, 18 m) and meth (12 f, 10 m) patients treated between 27 May 2015 and 1 January 2022 were analyzed retrospectively. There were no differences in age (median: 48 y) or Karnofsky performance index (median: 80). The IMI consisted of 5-day immunogenic cell death (ICD) therapies during TMZm: Newcastle disease virus (NDV) bolus injections and sessions of modulated electrohyperthermia (mEHT); subsequent active specific immunotherapy: dendritic cell (DC) vaccines plus modulatory immunotherapy; and maintenance ICD therapy. There were no differences in the number of vaccines (median: 2), total number of DCs (median: 25.6 × 10
), number of NDV injections (median: 31), and number of mEHT sessions (median: 28) between both groups. The median OS of 28 unmeth patients was 22 m (2y-OS: 39%), confirming previous results. OS of 22 meth patients was significantly better (
= 0.0414) with 38 m (2y-OS: 81%). There were no major treatment-related adverse reactions. The addition of IMI during/after standard of care should be prospectively explored.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Dendritic cells</subject><subject>Glioblastoma</subject><subject>Glioblastoma multiforme</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Methods</subject><subject>Neurosurgery</subject><subject>Newcastle disease</subject><subject>Oncolysis</subject><subject>Patients</subject><subject>Side effects</subject><subject>Temozolomide</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUk1P3DAQjaqigijn3ipLvfQSsOPEjnuotFAKkUA9lKpHy-uPXSPHTm2Hdvvr6xV0BYjxwaOZ957nWVNV7xA8xpjBEym81DGhDrYIsfZVddBA2tSEsPb1o3y_OkrpFpbAGFFC31T7mPQYdZgcVHbwyt5ZNQtn_2oFrmeX7RiUcGAYx9mHvNZRTBtgQgQLVboJ_LZ5DYYvlwj8tE7VN5tJg4vT609gAb5bv3IaDD5lm-eswfmfSUery6Bvqz0jXNJHD_dh9ePr-c3ZZX317WI4W1zVsu37XLOloawnQhkmlkYayChRmCpkpES96BRTqqGsFDpKSkDUa0WWAjdSia3Hw-rzve40L0etpPY5CsenaEcRNzwIy592vF3zVbjjjHUtZqQIfHwQiOHXrFPmo01SOye8DnPiDe0hpIg0XYF-eAa9DXP0xV5BUdY1rCmaO9RKOM2tN6G8K7eifEFbDBHEaDv38QuocpQerQxeG1vqTwgn9wQZQ0pRm51HBPl2QfizBSmM94-_Zof_vw74H-AFtxk</recordid><startdate>20230213</startdate><enddate>20230213</enddate><creator>Van Gool, Stefaan W</creator><creator>Makalowski, Jennifer</creator><creator>Van de Vliet, Peter</creator><creator>Van Gool, Stefanie</creator><creator>Sprenger, Tobias</creator><creator>Schirrmacher, Volker</creator><creator>Stuecker, Wilfried</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2601-0878</orcidid><orcidid>https://orcid.org/0000-0002-8102-5968</orcidid><orcidid>https://orcid.org/0000-0003-1253-9145</orcidid></search><sort><creationdate>20230213</creationdate><title>Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience</title><author>Van Gool, Stefaan W ; Makalowski, Jennifer ; Van de Vliet, Peter ; Van Gool, Stefanie ; Sprenger, Tobias ; Schirrmacher, Volker ; Stuecker, Wilfried</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-9bf7986adf9abfcf0976d37d1fcc18a5d9dd2797d1576666018ed6ba32cda0003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Dendritic cells</topic><topic>Glioblastoma</topic><topic>Glioblastoma multiforme</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Methods</topic><topic>Neurosurgery</topic><topic>Newcastle disease</topic><topic>Oncolysis</topic><topic>Patients</topic><topic>Side effects</topic><topic>Temozolomide</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Gool, Stefaan W</creatorcontrib><creatorcontrib>Makalowski, Jennifer</creatorcontrib><creatorcontrib>Van de Vliet, Peter</creatorcontrib><creatorcontrib>Van Gool, Stefanie</creatorcontrib><creatorcontrib>Sprenger, Tobias</creatorcontrib><creatorcontrib>Schirrmacher, Volker</creatorcontrib><creatorcontrib>Stuecker, Wilfried</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Gool, Stefaan W</au><au>Makalowski, Jennifer</au><au>Van de Vliet, Peter</au><au>Van Gool, Stefanie</au><au>Sprenger, Tobias</au><au>Schirrmacher, Volker</au><au>Stuecker, Wilfried</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-02-13</date><risdate>2023</risdate><volume>15</volume><issue>4</issue><spage>1194</spage><pages>1194-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and include the OS of MGMT promoter-methylated (meth) adults with GBM. Unmeth (10 f, 18 m) and meth (12 f, 10 m) patients treated between 27 May 2015 and 1 January 2022 were analyzed retrospectively. There were no differences in age (median: 48 y) or Karnofsky performance index (median: 80). The IMI consisted of 5-day immunogenic cell death (ICD) therapies during TMZm: Newcastle disease virus (NDV) bolus injections and sessions of modulated electrohyperthermia (mEHT); subsequent active specific immunotherapy: dendritic cell (DC) vaccines plus modulatory immunotherapy; and maintenance ICD therapy. There were no differences in the number of vaccines (median: 2), total number of DCs (median: 25.6 × 10
), number of NDV injections (median: 31), and number of mEHT sessions (median: 28) between both groups. The median OS of 28 unmeth patients was 22 m (2y-OS: 39%), confirming previous results. OS of 22 meth patients was significantly better (
= 0.0414) with 38 m (2y-OS: 81%). There were no major treatment-related adverse reactions. The addition of IMI during/after standard of care should be prospectively explored.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36831536</pmid><doi>10.3390/cancers15041194</doi><orcidid>https://orcid.org/0000-0002-2601-0878</orcidid><orcidid>https://orcid.org/0000-0002-8102-5968</orcidid><orcidid>https://orcid.org/0000-0003-1253-9145</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-02, Vol.15 (4), p.1194 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9954396 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antibodies Antigens Apoptosis Cancer therapies Care and treatment Cell cycle Cell death Chemotherapy Clinical trials Dendritic cells Glioblastoma Glioblastoma multiforme Immune system Immunogenicity Immunotherapy Lymphocytes Methods Neurosurgery Newcastle disease Oncolysis Patients Side effects Temozolomide Tumors Vaccines |
| title | Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A21%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Individualized%20Multimodal%20Immunotherapy%20for%20Adults%20with%20IDH1%20Wild-Type%20GBM:%20A%20Single%20Institute%20Experience&rft.jtitle=Cancers&rft.au=Van%20Gool,%20Stefaan%20W&rft.date=2023-02-13&rft.volume=15&rft.issue=4&rft.spage=1194&rft.pages=1194-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15041194&rft_dat=%3Cgale_pubme%3EA743010310%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2779529254&rft_id=info:pmid/36831536&rft_galeid=A743010310&rfr_iscdi=true |